DM-002

N/A

Report date: 2025/03/12 13:46:54

Base Information

Drug NameDM-002
Drug Alias NameDM-002DM002 (Danma)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionMucin-1 inhibitorsReceptor tyrosine-protein kinase erbB-3 inhibitors
TargetsMucin-1Receptor tyrosine-protein kinase erbB-3
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesAustraliaMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesDanma (Suzhou) Biomedical Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesXadcera Biopharmaceutical (Suzhou) Co LtdDanma (Suzhou) Biomedical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursProstatic NeoplasmsEndometrial Neoplasms +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A